Alzheimer's Research
To learn more about Alzheimer’s, memory loss and ongoing clinical trials in this area, visit our Alzheimer’s Disease Research page.
Learn MoreThe main purpose of this study is to compare donanemab to aducanumab on amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
Participants must have had slow or rapid change in memory for the last 6 months
Participant must have a reliable study partner with whom they have regular contact and who can provide written informed consent to participate and attend study appointments
Participants must not have a significant disease of the brain such as Parkinson's disease, multiple concussions, that affects completion of the study
Participants must not have history of heart attack or stroke, epilepsy or seizures
Participants must not have serious or unstable illness that could interfere with the analysis of the study or have a life expectancy <24 months
Participants must not have serious risk for suicide
Participants must not have a history of severe drug allergies
To learn more about Alzheimer’s, memory loss and ongoing clinical trials in this area, visit our Alzheimer’s Disease Research page.
Learn MoreTo learn more about neurological disorders and ongoing clinical trials in the area, visit our Neurological Disorders Research page.
A clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.